Drug Profile
Defibrotide - Jazz Pharmaceuticals
Alternative Names: Defibrotide sodium; Defitelio; Fraction P; JZP-381; Noravid; NS 73; ProciclideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Gentium
- Developer Fukushima Medical University; Gentium; Jazz Pharmaceuticals plc; Nippon Shinyaku; Swedish Orphan Biovitrum; University of California at San Francisco
- Class Antithrombotics; Nucleotide aptamers; Polydeoxyribonucleotides
- Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Veno-occlusive disorders
- Phase II Graft-versus-host disease; Neurological disorders; Thrombotic microangiopathies
- Market Withdrawal Deep vein thrombosis; Thrombosis
- No development reported Diabetic nephropathies; Multiple myeloma
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Graft-versus-host-disease(Prevention) in Italy (IV, Infusion)
- 11 Dec 2021 Efficacy and safety data from the phase III HARMONY trial in Veno-occlusive disorders presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 20 Apr 2021 Jazz Pharmaceuticals terminates phase II trial in Neurological disorders in USA as primary endpoints were unlikely to be met (NCT03954106)